BELLUS Health Inc.
BELLUS Health Inc. (BLU) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BLU · as of Jun 8, 2026
Key Statistics
Explore BELLUS Health Inc. Data
blu stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 6 · Buy rate: 33.3%
The BLU analyst consensus is Hold, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $14.75, representing +0.03% upside from the current price of $14.74.
Competitors & Peers
blu competitorsBLU
AMAM
ASTH
CALT
CINC
CTICStock Performance
Full HistoryAbout BELLUS Health Inc.
BELLUS Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, and founded in 1993. The firm focuses on developing therapeutic solutions for refractory chronic cough …
what is bellus health inc. · blu stock overview · bellus health inc. company profile · who is bellus health inc. ceo · blu NASDAQ · bellus health inc. headquarters · bellus health inc. business segments
About Stock Overview & Key Data
BELLUS Health Inc. (BLU) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 27, 2000. As of the latest trading session, BLU stock price is $14.74, with a market capitalization of $1.9B. The stock has returned +50.77% over the past 12 months and +73.06% year-to-date.
According to 6 Wall Street analysts, the consensus rating for BELLUS Health Inc. stock is Hold, with an average 12-month price target of $14.75. In fiscal year 2022, BELLUS Health Inc. reported revenue of $16000.00 and net income of -$76.1M. For detailed data — including BELLUS Health Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, BELLUS Health Inc. (BLU) stock price is $14.74. The stock is traded on NASDAQ under the ticker symbol BLU. The 52-week range is $6.38 – $14.76.